Platelet additive solutions: Current status

Immunohematology

Volumn 23, Issue 1, 2007, Pages 14-19

  Gulliksson, Hans ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; CITRATE SODIUM; GLUCONATE SODIUM; MAGNESIUM CHLORIDE; PLASMA SUBSTITUTE; PLATELET ADDITIVE SOLUTION; POTASSIUM CHLORIDE; PRESERVATION SOLUTION; SODIUM CHLORIDE; SODIUM DIHYDROGEN PHOSPHATE; UNCLASSIFIED DRUG;

CELL AGING; CHEMICAL COMPOSITION; PLASMA TRANSFUSION; PRIORITY JOURNAL; REVIEW; STORAGE; TEMPERATURE SENSITIVITY; THROMBOCYTE ACTIVATION; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION;

BLOOD PLATELETS; BLOOD PRESERVATION; HUMANS; PLATELET TRANSFUSION; PRESERVATIVES, PHARMACEUTICAL; TEMPERATURE;

EID: 34247197802     PISSN: 0894203X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Holme S. Effect of additive solutions on platelet biochemistry. Blood Cells 1992;18:421-30.
2. Holme S. Platelet storage in liquid environment. Transfus Sci 1994;15:117-30.
3. Högman CF. Aspects of platelet storage. Transfus Sci 1994;15:351-5.
4. Murphy S. The efficacy of synthetic media in the storage of human platelets for transfusion. Transfus Med Rev 1999;13:153-63.
5. Gulliksson H. Additive solutions for the storage of platelets for transfusion. Transfus Med 2000; 10:257-64.
6. Gulliksson H. Defining the optimal storage conditions for the long-term storage of platelets. Transfus Med Rev 2003;17:209-15.
7. Holme S, Heaton WA. In vitro platelet ageing at 22°C is reduced compared to in vivo ageing at 37°C. Br J Haematol 1995;91:212-8.
8. Oksanen K, Ebeling F, Kekomäki R, et al. Adverse reactions to platelet transfusions are reduced by use of platelet concentrates derived from buffy coat. Vox Sang 1994;67:356-61.
9. van Rhenen DJ, Vermeij K, Kappers-Klunne R, et al. Evaluation of a new citrate-acetate-NaCl platelet additive solution for the storage of white cell-reduced platelet concentrates obtained from half-strength CPD pooled buffy coats. Transfusion 1995;35:50-3.
10. Eriksson L, Kristensen J, Olsson K, et al. Evaluation of platelet function using the in vitro bleeding time and corrected count increment of transfused platelets: comparison between platelet concentrates derived from pooled buffy coats and apheresis. Vox Sang 1996;70:69-75.
11. Strindberg J, Berlin G. Transfusion of platelet concentrates: clinical evaluation of two preparations. Eur J Haemotol 1996;57:307-11.
12. Turner VS, Mitchel SG, Hawker RJ. More on the comparison of Plasma-Lyte A and PAS-2 as platelet additive solutions. Transfusion 1996;36:1033-4.
13. Hogman CF, Eriksson L, Wallvik J, et al. Clinical and laboratory experience with erythrocyte and platelet preparations from a 0.5 CPD Erythro-sol Opti System. Vox Sang 1997;73:212-9.
14. de Wildt-Eggen J, Nauta S, Schrijver JG, et al. Reactions and platelet increments after transfusion of platelet concentrates in plasma or an additive solution: a prospective, randomised study. Transfusion 2000;40:398-403.
15. Shanwell A, Diedrich B, Falker C, et al. Paired in vitro and in vivo comparison of apheresis platelet concentrates stored in platelet additive solution for 1 versus 7 days. Transfusion 2006;46:973-9.
16. Murphy S. Radiolabeling of PLTs to assess viability: a proposal for a standard. Transfusion 2004;44: 131-3.
17. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997;37:423-35.
18. van Rhenen, D, Gulliksson H, Cazenave JR et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.
19. McCullough J, Vesole DH, Benjamin RJ, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation. The SPRINT Trial. Blood 2004;104: 1534-41.
20. Snyder E, McCullough J, Slichter JS, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005;45:1864-75.
21. Janetzko K, Cazenave JP, Klüter H, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integration set. Transfusion 2005;45:1443-52.
22. van Rhenen, DJ, Gulliksson H, Cazenave JR et al. Therapeutic efficacy of pooled buffy-coat platelet components prepared and stored with a platelet additive solution. Transfus Med 2004;14:289-95.
23. Gewirtz AM, Schick B. Platelet production and function: megakaryocytopoiesis. In: Colman RW, Hirsh J, Marder VJ, et al., eds. Hemostasis and thrombosis. 3rd ed. Philadelphia: JB Lippincott, 1994:353-96.
24. Ringwald J, Walz S, Zimmermann R, et al. Hyperconcentrated platelets stored in additive solution: aspects on productivity and in vitro quality. Vox Sang 2005;89:11-8.
25. Ringwald J, Duerler T, Frankow O, et al. Collection of hyperconcentrated platelets with Trima Accel. Vox Sang 2006;90:92-6.
26. Sweeney J, Kouttab N, Holme S, et al. Storage of platelet-rich plasma-derived platelet concentrate pools in plasma and additive solution. Transfusion 2006;46:835-40.
27. Holme S, Heaton WA, Courtright M. Platelet storage lesion in second-generation containers: correlation with platelet ATP levels. Vox Sang 1987;53:214-20.
28. Gulliksson H, Sallander S, Pedajas I, et al. Storage of platelets in additive solutions: a new method for storage using sodium chloride solution. Transfusion 1992;32:435-40.
29. Shimizu T, Murphy S. Roles of acetate and phosphate in the successful storage of platelet concentrates prepared with an acetate-containing additive solution. Transfusion 1993;33:304-10.
30. Bertolini F, Murphy S, Rebulla R et al. Role of acetate during platelet storage in a synthetic medium. Transfusion 1992;32:152-6.
31. Guppy M, Whisson ME, Sabaratnam R, et al. Alternative fuels for platelet storage: a metabolic study. Vox Sang 1990;59:146-52.
32. Murphy S. The oxidation of exogenously added organic anions by platelets facilitates maintenance of pH during their storage for transfusion at 22°C. Blood 1995;85:1929-35.
33. Cesar J, DiMinno G, Alam I, et al. Plasma free fatty acid metabolism during storage of platelet concentrates for transfusion. Transfusion 1987;27: 434-7.
34. Gawaz M, Ott I, Reininger AJ, et al. Effects of magnesium on platelet aggregation and adhesion. Thromb Haemost 1994;72:912-8.
35. Weis-Fogh US. The effect of citrate, calcium, and magnesium ions on the potassium movement across the human platelet membrane. Transfusion 1985;25:339-42.
36. Kinlough-Rathbone RL, Packham MA, Mustard JF. Platelet aggregation. In: Harker LA, Zimmerman TS, eds. Methods of hematology: measurements of platelet function. New York: Churchill Livingstone, 1984:64-91.
37. Gulliksson H. Storage of platelets in additive solutions: the effect of citrate and acetate in in vitro studies. Transfusion 1993;33:301-3.
38. de Wildt-Eggen J, Schrijver JG, Bins M, et al. Storage of platelets in additive solutions: effects of magnesium and potassium. Transfusion 2000;42: 76-80.
39. Gulliksson H, AuBuchon JP, Vesterinen M, et al. Storage of platelets in additive solutions: a pilot study of the effects of potassium and magnesium. In vitro studies. Vox Sang 2002;82:131-6.
40. Gulliksson H, AuBuchon JP, Cardigan R, et al. Storage of platelets in additive solutions: a multicentre study of the in vitro effects of potassium and magnesium. Vox Sang 2003;85: 199-205.
41. Hunter S, Nixon J, Murphy S. The effect of the interruption of agitation on platelet quality during storage for transfusion. Transfusion 2001;41: 809-14.
42. van der Meer PF, Gulliksson H, AuBuchon JP, et al. Interruption of agitation of platelet concentrates: effects on in vitro parameters. Vox Sang 2005; 88:227-34.